Head-to-head · WeighScore
bmiMD vs OnlineSemaglutide.org
By GLP-1 ScorecardUpdated
Score comparison
bmiMD has the higher recorded score — 79.2/100 to 70.1/100.
bmiMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | bmiMD | OnlineSemaglutide.org |
|---|---|---|
| WeighScore | 79.2/100 | 70.1/100 |
| Grade | C+ | C |
| Site position | #29 | #123 |
| Semaglutide | $159/mo month-to-month ($119/mo equivalent with $1,428 prepaid for 12 months) | $150/mo (compounded) |
| Tirzepatide | $249/mo month-to-month ($179/mo equivalent with $2,148 prepaid for 12 months) | $399/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #29 · C+
Strengths
- Advertises the same price across prescribed doses for each selected injection plan
- Publishes compounded semaglutide and tirzepatide injection plans
- Every rung of both ladders is published with the total charge beside each per-month figure
- All 50 states
What to consider
- The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
- The annual $119 and $179 monthly equivalents require $1,428 or $2,148 paid upfront for 12 months
- A struck-through $228.60 and $349.20 sit above the ladders under a standing LIMITED TIME label, with no published basis
- Neither the compounding pharmacy nor the prescribing group is named on the product pages
Site position #123 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
- Multiple administration formats
What to consider
- Limited public information on program details
Featured provider
bmiMD
bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.